-
Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator
Why Has This September 2024 European Medicines Agency (EMA) Action Not Been Followed by FDA in US? (Posted by Tom Lamb at Drug Injury Watch) One of the primary issues in the increasing number of…
-
Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma
While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years (Posted by Tom Lamb at Drug Injury Watch) Drug injury lawsuits that involve the contraceptive injection Depo-Provera being…
-
Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024
AstraZeneca Says "while discussions with the FDA are ongoing, Andexxa will remain on the US market." (Posted by Tom Lamb at Drug Injury Watch) In our November 21, 2024 article, "Do Andexxa Risks Outweigh Benefits…
-
Novo Nordisk Semaglutide Drug Ozempic Linked to Vision Loss, Doubling the Risk: December 2024 Update
European Drug Regulators Are Investigating Semaglutide-Related NAION Cases Presented in Two Danish Studies (Posted by Tom Lamb at Drug Injury Watch) According to this December 18, 2024, Reuters news report, "Novo Nordisk's Ozempic faces EU…